Some bio investors have a perverse incentive to advocate for policies that will keep US drug prices unreasonably high. And self deception is easy for many, since the most obvious counterfactual is a system that encourages fewer actual cures to get to market.
It can both be true that single-payer in the United States would be a boon to its people and that, without excessive USA healthcare profits, there will be a weaker incentive for drug discovery, globally.
-
-
There are ways to reduce costs that do not involve single payer.
-
Such as?
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.